Related Articles
Journal Digest: May 3
This week’s collection of the latest dermatologic studies includes social determinants of health in HS, JNJ-77242113 for moderate to severe plaque psoriasis, sonidegib for locally…
QUIZ: Melanoma Classification and Staging
Click here to read more and answer our quiz questions in recognition of Skin Cancer Awareness Month and Melanoma Monday.
Alpha Tau to Conduct Trial of Alpha DaRT Technology In Patients With Recurrent Squamous Cell Carcinoma
Robert Den, MD, and Alpha Tau are seeking motivated investigators who may be interested in participating in the trial.
Recognizing Melanoma and Skin Cancer Awareness Month
Our May issue of Dermatology Times spotlights melanoma/skin cancer awareness and more.
Navigating Plaque Psoriasis Progress: A Year in Review
Experts in dermatology provide a comprehensive year in review regarding the management of plaque psoriasis, highlighting key therapeutic approvals from 2023. The discussion will highlight…
QUIZ RECAP: Test Your Knowledge of Rosacea Research and Innovations
Earlier this week, we shared our fourth and final Rosacea Awareness Month quiz. Review the answers and your responses below.
Reviewing Concerns For Mental Health and Well-Being in Dermatologic Conditions
May is Mental Health Awareness Month, and Dermatology Times is spotlighting the common relationship between skin conditions and struggles with mental health, quality of life,…
The Mechanisms of Action of AD Treatments
Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, comment on the newer treatments in AD, highlighting the positive impact these agents have had…
JAK Inhibitors Show Favorable Risk-Benefit Profile In Vitiligo, Especially for Facial Cases
A new review highlighted JAK inhibitors’ role in vitiligo treatment, emphasizing varying benefits, facial efficacy, and potential for sustained responses.
Skin Cancer Breakthroughs, Prevention, and Treatment Advances During the Past Year
This recap of skin cancer innovations accompanies the cover story of our May publication.